Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

McGuire, Darren K., Marx, Nikolaus, Mulvagh, Sharon L., Deanfield, John E., Inzucchi, Silvio E., Pop-Busui, Rodica, Mann, Johannes F.E., Emerson, Scott S., Poulter, Neil R., Engelmann, Mads D.M., Ripa, Maria Sejersten, Hovingh, G. Kees, Brown-Frandsen, Kirstine, Bain, Stephen C., Cavender, Matthew A., Gislum, Mette, David, Jens-Peter, Buse, John B.·2025·New England Journal of Medicine
DOI 10.1056/nejmoa2501006

Cited by (438)

Items 201–300 of 438

  1. The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection Fraction
    Rachel Su Min Lee, Jas‐mine Seah, Sara Baqar, Piyush Srivastava, Eylem Levelt, Angeline S. Leet, Andrew I. MacIsaac, Elif Ilhan Ekinci, Richard J. MacIsaac · 2026 · Medicina
  2. Oral versus injectable GLP-1 receptor agonists in clinical practice
    Viktor Rotbain Curovic, Peter R Rossing · 2026 · Nephrology Dialysis Transplantation
  3. SGLT2 inhibitors and GLP-1 receptor agonists in atrial fibrillation treatment: Clinical evidence and mechanistic insights
    Yue Fan, Xi Chen, Xingming Cai, Yugang Dong, Chen Liu, Yili Chen, Gregory Y.H. Lip, Wengen Zhu · 2026 · Metabolism
  4. Stratification of direct retail pharmacotherapy costs for type 2 diabetes mellitus and obesity in Russia: an analysis of guideline-recommended regimens
    Arthur Anatolievich Lee, D. О. Borisov, V. S. Novikova, Dmitry Alexandrovich Kashirskikh, Victoria Alexandrovna Khotina, Vagif Ali oglu Gasanov, Andrey Valentinovich Vasiliev · 2026 · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology
  5. Incretin analogues as cardiovascular agents: a state-of-the-art review
    Diego Araiza Garaygordobil, Jorge E. Rico-Fontalvo, Betsabe Hernández-Balbuena, Mónica Vinay, Mauricio Gonzalez-Arias · 2026 · Frontiers in Endocrinology
  6. Evidence-Based Cardiovascular–Kidney–Metabolic Therapies in Kidney Transplant Recipients
    Gautam R. Shroff, Xingxing S. Cheng, Ara Gharabagi, Chien-Jung Lin, Mina Mecheal Benjamin, Krista L. Lentine · 2026 · Clinical Journal of the American Society of Nephrology
  7. SRT1720-loaded exosome-mimetic nanovesicles promote mitophagy via SIRT1/PARKIN activation to ameliorate diabetic cerebral infarction in a preclinical rat model
    Qifeng Huang, Fang Zhao, Bo Sun, Xie Yang, Miao Chen · 2026 · International Journal of Pharmaceutics X
  8. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial
    Marc P. Bonaca, Mario Enrico Canonico, Na Li, William J. Sasiela, Steven E. Nissen, Abraham Michael Lincoff, Stephen James Nicholls · 2026 · Circulation
  9. Glucagon-like peptide-1 receptor agonists and risk of diabetic retinopathy in type 2 diabetes: A systematic review and network meta-analysis of randomized clinical trials
    Amparo Ortiz-Seller, José Tomás Real, Esteban Jesús Morcillo, J.L. Ortiz · 2026 · Survey of Ophthalmology
  10. Risk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
    Yuanyuan Zhong, Xing Tan, Ling Zhang, Cangui Wu · 2026 · Frontiers in Pharmacology
  11. CARDIOVASCULAR OUTCOMES IN DIABETIC PATIENTS TREATED WITH SGLT2I AND GLP1–RA: SYSTEMATIC REVIEW AND META–ANALYSIS
    G. Marino, Alessandro Alonzo, Alessandro Aiello, Stefania Angela Di Fusco, Stefano Aquilani, Furio Colivicchi · 2025 · European Heart Journal Supplements
  12. Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data
    Gian Paolo Fadini, Enrico Longato, Sara Poletto, Andrea Giaccari, Mariangela Ghiani, Marco Strazzabosco, Maddalena Trombetta, Giuseppe Penno, Angelo Avogaro, Anna Solini et al. · 2025 · Diabetes Obesity and Metabolism
  13. The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
    Silvia Ana Luca, Raluca Malina Bungau, Sandra Lazăr, Andreea Herascu, Laura Gaiţă, Vlad Florian Avram, Bogdan Timar · 2025 · Journal of Clinical Medicine
  14. Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network
    Abigail Postema, Jordy Gaspersz, Brenda N Baak, Eline L. Huisman, Charlotte Hoogstraten, Lise Meinicke Hagelund, Fernie J. A. Penning‐van Beest, Jetty A. Overbeek · 2025 · Diabetes Obesity and Metabolism
  15. Intersecting Burdens: Type 2 Diabetes Diagnosis, Risk, and Pharmacological Management Among People Living With HIV
    Rachel Arnold, Briann Fischetti, Maria Longo · 2025 · Journal of Pharmacy Practice
  16. Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
    Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Cynthia Melissa Valério, Fernando M. A. Giuffrida, Larissa Neto Espíndola, Maria Cristina de Oliveira Izar, Celi Marques-Santos, Cláudia Maria Vilas Freire, Carlos Japhet da Matta Albuquerque, Antônio Carlos Palandri Chagas et al. · 2025 · Revista Brasileira Ginecologia e Obstetrícia
  17. Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis
    Niloofar Seighali, Mohammad Sadra Gholami Chahkand, Mandana Ebrahimzade, Farzin Tahmasbi Arashlow, Seyede Parmis Maroufi, Parnian Rahnama, Mohammad Hassan Matin, Alireza Khodayari Javazm, Pouya Ebrahimi, Khurram Nasir et al. · 2026 · BMC Pharmacology and Toxicology
  18. GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
    Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, Yitian Yang, Shuang Lv, Mengrong Miao, Wan‐Ming Chen, Szu‐Yuan Wu, J. Zhang · 2026 · Diabetes Obesity and Metabolism
  19. Pharmacotherapy for obesity management—Emphasizing the role of GLP-1 receptor agonist-based therapeutics
    Bruce A. Warden, Paul Barton Duell, John D. Bucheit, Jonathan Q. Purnell · 2026 · Journal of clinical lipidology
  20. Secondary Prevention in Older Adults
    Jong Kun Park, Onyinye Sylvia Ugoala, Ugochukwu Jerome Ebubechukwu, Anandita Agarwala · 2026 · Clinics in Geriatric Medicine
  21. Relative Efficacy of Next‐Generation Incretin Therapies for Cardio‐Renal Protection in Type 2 Diabetes: Evidence From a Network Meta‐Analysis
    Thi-Phuong-Thao Pham, Thi‐Minh‐Nhat Vo, The-Anh Nguyen, Tien‐Phat Dao, N. T. Ngo, Thi‐Thuy‐Duong Le, Thanh‐Thien Tran, Thanh‐Huong Pham, Dang‐Mai‐Linh Huynh, Hai‐Anh Ha · 2026 · Diabetes Obesity and Metabolism
  22. A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
    Andrew-Hyun Lee, Deborah Jane Holmes-Walker · 2026 · Healthcare
  23. Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0 mg in Type 2 Diabetes
    Genki Edward Sato, Hiroshi Uchino, Kota Takuma, Manabu Saito, Ayako Fuchigami, Yoko Iwata, Fukumi Yoshikawa, Takahisa Hirose · 2026 · Diabetes Therapy
  24. Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model
    Lay-Har Lim, Eric S. H. Lau, Juliana Nga Man Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, S P Chan, Soo Kyung Lim, Andrea O. Y. Luk, Juliana C.N. Chan · 2026 · Diabetes Obesity and Metabolism
  25. The WHO Essential Medicines List can help to unlock access to GLP-1 therapies for metabolic syndrome
    Kevin C Pottie, Kiran Saluja, Omar Dewidar, Ammar Saad, Hohammad Hajizadeh, Lorenzo Moja, Syed Sibte Raza Abidi · 2026 · Nature Health
  26. Effect of intensive blood pressure and blood glucose control on cardiovascular outcomes driven by reductions in cardiovascular death and nephropathy: win ratio analysis of ADVANCE trial
    Séverine Bompoint, Laurent Billot, Anushka A Patel, Mark Woodward, Katie Harris, Stephen B. Harrap, Giuseppe Mancia, Neil R Poulter, John Philip Chalmers · 2026 · European Heart Journal - Cardiovascular Pharmacotherapy
  27. A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity
    Blessing T Ojinna, Sara Tariq, Osamede Agho, Rabia Channa, Gurdeep Singh · 2026 · Cureus
  28. Kardiovaskuläre Erkrankungen und Herzinsuffizienz bei Diabetes: Diagnostik und Management (Update 2026)
    Matthias Wolfgang Heinzl, Michael Resl, Julian Maier, Clemens Steinwender, Jürgen Falkensammer, Paul Fellinger, Thomas Steinmaurer, Christoph H. Saely, Friedrich Hoppichler, Harald Stingl et al. · 2026 · Wiener klinische Wochenschrift
  29. Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study
    Álvaro Galiano, Fernando Notario-Pérez · 2026 · Journal of Computer-Aided Molecular Design
  30. Incretins for type 2 diabetes
    Esther Min, Andrew Goyette, Elaine Young, Katherine Moon, Natalie J. Bellini, Diana M. Isaacs · 2026 · Canadian Journal of Physiology and Pharmacology
  31. Nationwide Real‐World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in F inland
    Atte Vadén, Mari Lahelma, LALLI NURMI, Eija Heikkilä, Hannu Vessari, Hanne Luoto, Tero T Saukkonen, Leo Niskanen · 2026 · Diabetes Obesity and Metabolism
  32. Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials
    Matthew Todd, Patrick Savage, Michael Campbell, Meadhbh Hogg, Mark McKane, Ian B A Menown · 2026 · Advances in Therapy
  33. Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists in patients without obesity: a systematic review and meta-analysis of randomized controlled trials
    Saad Ahmed Waqas, Muhammad Ibrahim, Muhammad Ahmed, Muhammad Waqas, Jazza Aamir, Marat Fudim, Muzammil H. Musani, Gregg C. Fonarow, Stephen John Greene · 2026 · Journal of Diabetes & Metabolic Disorders
  34. Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes
    Joshua J. Neumiller, Yihong Deng, KAVYA SINDHU SWARNA, Eric C. Polley, Jeph S. Herrin, Rodolfo Javier Galindo, Guillermo E. Umpierrez, Joseph S. Ross, Mindy M. Mickelson, Kate Dryden et al. · 2026 · American Journal of Kidney Diseases
  35. Cardiovascular Efficacy of GLP ‐1 Receptor Agonists by Kidney Function: An Updated Meta‐Analysis of Randomized Trials Including the SOUL Trial
    Masashi Hasebe, Chen‐Yang Su, Daisuke Yabe, Satoshi Yoshiji · 2026 · Diabetes Obesity and Metabolism
  36. Impact of glucagon-like peptide-1 receptor agonists with guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and type 2 diabetes
    Yuki Kokura, Takefumi Kishimori, Takao Kato, Yoshihiro Iwasaki, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Takehiro Matsumoto, Takafumi Yagi et al. · 2026 · Diabetes Research and Clinical Practice
  37. Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies
    José Seijas‐Amigo, Ángel Salgado‐Barreira, Sonia Eiras, Susana Arias-Rivas, Gemma Rodríguez-Carnero, Moisés Rodríguez‐Mañero, José Ramón González‐Juanatey · 2026 · European Heart Journal Open
  38. Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
    Jan Kafol, Borut Jug, Zlatko Fras · 2026 · Cells
  39. Endothelial Shear-Stress-Responsive Gene Adenylate Cyclase 4 Suppresses Atherosclerosis by Inhibiting cAMP/PKA-NF-κB Mediated Vascular Inflammation
    Wenzhen Bao, Jianfei Xu, Wenjian Nian, Peilin Pang, Wenrun Wu, Zijian Huang, Lin Hu, Qi Zhang, Wenqi Pan, Xiaotong Gao et al. · 2026 · Arteriosclerosis Thrombosis and Vascular Biology
  40. PharmaPlain: SOUL trial looking at the effect of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease
    Rhonda E. Monroe, Nikolaus Marx, Darren K. McGuire · 2026 · European Heart Journal - Cardiovascular Pharmacotherapy
  41. Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
    Susan van Maren, Eveline P.M. van Doorn, Mark M. Smits, Cees J. Tack, Elisabeth F. C. van Rossum, Saloua El Messaoudi · 2026 · Netherlands Heart Journal
  42. Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Melanie Jane Davies, Vanita R. Aroda, Mandeep Singh Bajaj, Nuha A. ElSayed, Francesco Giorgino, Jennifer Green, Rita Rastogi Kalyani, Nisa M. Maruthur, Chantal Mathieu, Sylvia E. Rosas et al. · 2026 · Diabetologia
  43. Weekly Journal Scan: Effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes and high risk profile
    Giovanna Gallo, Massimo Volpe · 2025 · European Heart Journal
  44. Obesity Medications Beyond Glucose Control and Weight Reduction: Updates on the Expanding Benefits, Clinical Challenges, and Future Directions
    Spyridon Ntelis, Brian S. Wojeck · 2025 · Current Hypertension Reports
  45. Oral semaglutide and reduction in major adverse cardiovascular events
    Paul Barton Duell, Kevin Carl Maki · 2025 · Journal of clinical lipidology
  46. Oral Semaglutide and Cardiovascular Outcomes
    Marcel Catão F Dos Santos, Natália Nóbrega de Lima, Josivan G Lima · 2025 · New England Journal of Medicine
  47. New Insights Into Delaying Renal Progression: Cardiovascular, Renal & Metabolic Medicine
    Rabbani Mahmoud Daoud, Sebastian Spencer, Robert Desborough, Sunil Bhandari · 2026 · British Journal of Hospital Medicine
  48. Expanding cardiovascular indications for semaglutide: results from the SOUL and STRIDE trials
    Karina Huynh · 2025 · Nature Reviews Cardiology
  49. News in cardiovascular pharmacotherapy from the ACC.25 Meeting
    Eva Delpón, Ricardo Caballero, Juan Luis Tamargo · 2025 · European Heart Journal - Cardiovascular Pharmacotherapy
  50. Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial
    2025 · Texila international journal of academic research
  51. The Role of GLP-1R and GIPR Agonism in Heart Failure
    Phelopater Sedrak, Kim Alexander Connelly · 2025 · Canadian Diabetes & Endocrinology Today
  52. Chez les personnes avec diabète de type 2 à risque cardiovasculaire élevé, est-ce que le sémaglutide oral est efficace et sécuritaire pour diminuer les évènements cardiovasculaires majeurs comparativement au placébo ?
    Alexandre Mutchmore, Mathieu N. Labossière, Michel Cauchon, M.-É. Plourde, Luc Lanthier · 2025 · La Revue de Médecine Interne
  53. From Editor-in-Chief: On issue, our rank – trail of pandemic period but increase in quality and SDG, congresses, trials, guidelines and important documents, news on prevention
    Gulmira Kudaiberdieva · 2025 · Heart Vessels and Transplantation
  54. Cardiovascular risk reduction in patients with diabetes mellitus and/or chronic kidney disease—an update
    Katharina Marx-Schütt · 2025 · Herz
  55. Response to “Weight‐loss drugs like Wegovy could lead to an increased risk of fragility fractures in population at risk”
    Robert F. Kushner, Donna H. Ryan, Nina Majlund Harder-Lauridsen, Ole Kleist Jeppesen, Klaus Kallenbach, Abraham Michael Lincoff, Ildiko Lingvay · 2025 · Obesity
  56. Oral semaglutide in HFpEF: Real-world evidence and causal considerations
    Victoria Catalán, Gema Frühbeck, Javier Gómez‐Ambrosi · 2025 · European Journal of Internal Medicine
  57. CKD–Mineral and Bone Disorder
    Eleanor DeLand Lederer · 2025 · Nephrology Self-Assessment Program
  58. Use of Semaglutide After Acute Coronary Syndrome - Design and rationale of a retrospective observational study
    Marco Biasin · 2025 · medRxiv
  59. Use of oral Semaglutide after Acute Coronary Syndrome - Design and rationale of a prospective observational study
    Marco Biasin · 2025 · medRxiv
  60. Clinical Science at the Intersection of Cardiovascular, Metabolic, and Renal Diseases: New Approaches
    Heinz Drexel, Andreas Festa, Dan Atar · 2025 · Cardiology
  61. Research Progress in Fracture Risk Assessment and Treatment for T2DM Complicated with Osteoporosis
    诗怡 刘 · 2025 · Advances in Clinical Medicine
  62. Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity. Diabetes Care 2025;48:489–493
    Matthew M.Y. Lee, Darren K. McGuire, Naveed A. Sattar · 2025 · Diabetes Care
  63. Semaglutide’s dilemma: A lifesaver with a price?
    Niladri Sekhar Dingal · 2025 · Annals of Medical Science and Research
  64. Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials
    Mohammed El‐Sheikh, Christina Dam Bjerregaard Sillassen, Frederik Dencker Wisborg, Jens Dahlgaard Hove, Carsten Dirksen, Matthew M.Y. Lee, Janus Christian Jakobsen, Johannes Grand · 2025 · BMJ Open
  65. Cardiovascular and kidney benefits of GLP ‐1 receptor agonists across large randomized placebo‐controlled trials
    Satoshi Yoshiji, Nobuya Inagaki · 2025 · Journal of Diabetes Investigation
  66. Semaglutid schützt auch bei oraler Applikation
    Susanne Krome · 2025 · DMW - Deutsche Medizinische Wochenschrift
  67. Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis
    Abigail Rai, Mahesh Kolli, Gaurav Pratap Singh, Rishu Rishu, Chao Yuan Li Cai, Hariharasudhan Balaji, Bendangjungla Pongen, Sandra Joy, Shahid Sai A.K. · 2025 · Cureus
  68. Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling
    Samit Ghosal, Anuradha Ghosal · 2025 · Diabetes Therapy
  69. The SOUL trial: another important study for the reduction of CV risk in individuals with type 2 diabetes
    Nikolaus Marx · 2025 · Cardiovascular Research
  70. Oral Semaglutide in Adults with Overweight or Obesity
    Sean Wharton, Ruben Duque do Vale, William Timothy Garvey · 2025 · New England Journal of Medicine
  71. Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits
    Naseem Eisa, Omar Barood · 2025 · Endocrine Practice
  72. Secondary Prevention After Myocardial Infarction: Bridging Evidence to Practice
    Kevin Haddad, Laurie‐Anne Boivin‐Proulx, Samer Mansour · 2025 · Canadian Cardiology Today
  73. From Classic to Contemporary, Evolving Therapies in Diabetic Kidney Disease: The Point of View of the Nephrologist and the Diabetologist
    Micaela Gentile, Marta D’Angelo, Maria Rosaria Varì, Andrea Mario Bolla, Maurizio Bianco, Roberto Scarpioni · 2025 · Diabetology
  74. Exciting new developments in clinical lipidology: Updates from the Food and Drug Administration and the American Heart Association
    Paul Barton Duell, Kevin Carl Maki · 2025 · Journal of clinical lipidology
  75. Nuevo algoritmo de redGDPS 2026: de la glucemia al paciente
    Francisco Javier García Soidán, Sara Artola Menéndez, Luis Ávila Lachica, Óscar Baro Pato, Nùria Casado Pradas, Carlos Hernández Teixidó, Noelia Sanz Vela, Inés Mera-Gallego, Enrique Carretero-Anibarro · 2025 · Diabetes práctica
  76. Diabetes mellitus und Herz
    Katharina Marx-Schütt, Thomas M. Forst, Andreas L. Birkenfeld, Andreas Zirlik, Dirk Müller‐Wieland, Nikolaus Marx · 2025 · Diabetologie und Stoffwechsel
  77. Decoupling weight loss from organoprotective benefits in GLP-1RA, dual agonists, and SGLT2I therapy: A narrative review
    Gaurab Bhaduri, SUPRATIK BHATTACHARYYA, Shatavisa Mukherjee, Rutul A. Gokalani · 2026 · Acta Diabetologica
  78. Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
    Takefumi Kishimori, Takao Kato, Yoshihiro Iwasaki, Takenobu Shimada, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Takehiro Matsumoto, Takafumi Yagi et al. · 2026 · Diabetes Obesity and Metabolism
  79. Patients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality
    A Velasco, Ignacio Pascual Ramos, Pablo Rodríguez Alonso, Celia Denche Sanz, Rocío Tello, Jorge Solís · 2026 · Revista Clínica Española (English Edition)
  80. Pacientes postinfarto agudo de miocardio: potencial de semaglutida en pronóstico de reducción de eventos y mortalidad
    A Velasco, Ignacio Pascual Ramos, Pablo Rodríguez Alonso, Celia Denche Sanz, Rocío Tello, Jorge Solís · 2026 · Revista Clínica Española
  81. Orale Einnahme von 25 mg Semaglutid bei Erwachsenen mit Übergewicht oder Adipositas
    Alida Finze, Mirko Otto, Christoph Reißfelder · 2026 · Die Chirurgie
  82. Risk-Based Stratification Approach for Cardiovascular-Kidney-Metabolic Syndrome Stage 2 Using a Simple Algorithm
    Zhejia Tian, Maxim Sternberg, Jonas Michael Willerding, Kai M. Schmidt-Ott, Anette Melk, B. Schmidt · 2026 · medRxiv
  83. A betegség lefolyását módosító gyógyszeres kezeléssel szerzett tapasztalataink 2-es típusú diabetes mellitusos betegeinknél egy egycentrumos retrospektív vizsgálat eredményei alapján
    Ágnes Diószegi, Hajnalka Lőrincz, Molnár Ágnes, Judit Kaluha, Nóra Homoródi, Éva Katona, Mariann Harangi · 2025 · Diabetologia Hungarica
  84. merging Advances in Oral and Injectable Anti-Obesity Pharmacotherapies: A Review of Current Evidence
    Sten Madsbad · 2025 · Medical Research Archives
  85. Response to STRIDE: semaglutide in peripheral artery disease and type 2 diabetes – Authors' reply
    Marc P. Bonaca, Joakim Nordanstig, Bernhard H. Ludvik, Alex N. Videmark, Subodh Verma · 2026 · The Lancet
  86. Diabetes mellitus und Herz
    Katharina Marx-Schütt, Thomas M. Forst, Andreas L. Birkenfeld, Andreas Zirlik, Dirk Müller‐Wieland, Nikolaus Marx · 2026 · Die Diabetologie
  87. Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions
    Diana De Oliveira-Gomes, Alfonso Martinez de Majo, Angie D. Ardila-Delgado, Sara S. Inglis, Stacy A. Mandras, Juan Francisco Loro-Ferrer, Adrian daSilva‐deAbreu · 2026 · Current Atherosclerosis Reports
  88. Use of semaglutide after acute coronary syndrome: an exploratory retrospective study
    Marco Biasin, M Stratinaki, Nicolò Cordioli, Ilaria Armani, Sara De Giovanni, Georgios Aletras, Davide Betta, Luca Callegarin, Alessia Gambaro, Giovanni Morani · 2026 · Journal of Cardiovascular Medicine
  89. Documento de posicionamiento de SEMERGEN sobre la enfermedad renal crónica
    N. Pérez-León, José Polo García, M.P. Alonso-Álvarez, Lourdes Martínez-Berganza-Asensio · 2026 · Medicina de Familia SEMERGEN
  90. Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study
    Hsiao-Yuan Hsu, Hon-Yi Shi · 2026 · Diabetes Research and Clinical Practice
  91. Inkretinmimetika und Schilddrüsenkrebs: Gibt es ein Risiko?
    Verena Parzer · 2026 · Journal für Endokrinologie Diabetologie und Stoffwechsel
  92. Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2025
    Carl A. Andersen, Mark L. Wieland, Shari L. Bornstein, Jill M. Huber, Terin T. Sytsma, Mohammed Nadir Bhuiyan, Majken T. Wingo · 2026 · The American Journal of Medicine
  93. Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Gianmarco Adinolfi, Valeria Milia, Boris Dinkov, Galya Stavreva · 2026 · Endocrines
  94. Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
    Naveed A. Sattar · 2026 · Elsevier eBooks
  95. Research Progress on the Association between Chronic Diabetes Complications and Adverse Outcomes
    歆童 朱 · 2026 · Hans Journal of Food and Nutrition Science
  96. Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure
    Thomaz Alexandre Costa, Amanda Ruth Vest, Josephine Harrington · 2026 · Current Opinion in Cardiology
  97. Tirzepatide and semaglutide: different twins?
    Arturo Cesaro, Vincenzo Acerbo, Paolo Calabrò · 2026 · European Heart Journal Supplements
  98. Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes
    Mitsuhisa Komatsu, Hiroshi Kobayashi, Satoshi Tsuboi, Hirotaka Watada · 2026 · Diabetology International
  99. Effect of Oral Semaglutide on Cardiovascular Outcomes in Type 2 Diabetes by Extent of Vascular Disease
    Matthew Aaron Cavender, Nikolaus Marx, Sharon L. Mulvagh, John Eric Deanfield, John B. Buse, Silvio E. Inzucchi, Rodica Pop‐Busui, Johannes F.E. Mann, Scott S. Emerson, Neil R Poulter et al. · 2026 · Journal of the American College of Cardiology
  100. Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes
    Giovanna Liuzzo, Carlo Patrono · 2026 · European Heart Journal